Preview

User

Not a user? Register with this site Forgot your password?

Russian Journal of Cardiology

Advanced search

Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial

https://doi.org/10.15829/29/1560-4071-2020-4167

Abstract

At the online meeting held on September 3, 2020, the results of the international multicenter trial EMPEROR-REDUCED were considered. Number of proposals and recommendations for the further study of cardiovascular and renal effects of empagliflozin and its practical use in heart failure patients were agreed.

About the Authors

G. P. Arutyunov
Eurasian Association of Therapists; Pirogov Russian National Research Medical University
Russian Federation

MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, President of the Eurasian Association of Therapists, Head of the Department of Internal Medicine and General Physiotherapy Pirogov Russian National Research Medical University.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


A. G. Arutyunov
Eurasian Association of Therapists; Pirogov Russian National Research Medical University
Russian Federation

MD, PhD, Associate Professor, Secretary General of Eurasian Association of Therapists, Professor of the Department of Internal Medicine and General Physiotherapy Pirogov Russian National Research Medical University.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


E. I. Tarlovskaya
Eurasian Association of Therapists; Privolzhsky Research Medical University
Russian Federation

MD, PhD, Professor, head of the Department of therapy and cardiology, Volga Research Medical University, Chairperson of Eurasian Association of Therapists branch in Nizhny Novgorod.

Moscow; Nizhny Novgorod.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


A. S. Ametov
Russian Medical Academy of Continuous Professional Education
Russian Federation

MD, PhD, Professor, Honored Scientist of the Russian Federation, Head of the Department of Endocrinology «Russian Medical Academy of Continuous Professional Education», Laureate of the State Program of the Belorussian Soviet Socialist Republic.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


N. G. Vinogradova
Privolzhsky Research Medical University
Russian Federation

PhD, Associate Professor of the Department of Therapy and Cardiology Privolzhsky Research Medical University.

Nizhny Novgorod.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


A. A. Garganeeva
Tomsk National Research Medical Center
Russian Federation

MD, PhD, Professor,  Head of the Department of Myocardial Pathology  (Cardiology Research Institute) Tomsk National Research Medical Center.

Tomsk.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


M. G. Glezer
I.M. Sechenov First Moscow State Medical University
Russian Federation

MD, PhD, Professor of the Department of Preventive and Emergency Cardiology Faculty of Postgraduate Professional Education , Head of the Laboratory of Functional Research Methods and Rational Pharmacotherapy of Cardiovascular Diseases of the I.M. Sechenov First Moscow State Medical University.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


I. V. Zhirov
National Medical Research Center for Cardiology
Russian Federation

MD, PhD, Professor Leading Researcher of the Department of Myocardial Diseases and Heart Failure National Medical Research Center for Cardiology.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


M. V. Ilyin
Yaroslavl State Medical University
Russian Federation

MD, PhD, Associate Professor at the Department of Therapy at the Institute of Postgraduate Education, Yaroslavl State Medical University, Dean of the faculty of highly qualified personnel training. Head of the Department of Therapy named after Professor E.N.Dormidontov.

Yaroslavl.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


N. A. Koziolova
Perm State Medical University
Russian Federation

MD, PhD, professor, Head of the Introduction to Internal Medicine Dept No 2, Perm State Medical University. Chairperson of the Eurasian Association of Therapists branch in Perm.

Perm.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


A. O. Konradi
V.A. Almazov National research medical center of Russian Ministry of Healthcare
Russian Federation

Сorresponding member of the Russian Academy of Sciences. MD, PhD, Professor, Deputy General Director of scientific work Director of National research medical center named after V. A. Almazov of Ministry of Healthcare of Russia.

Saint-Petersburg.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


A. Yu. Lebedeva
Pirogov Russian National Research Medical University
Russian Federation

MD, PhD, Professor of the Department of Hospital Therapy No. 1 Pirogov Russian National Research Medical University.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


Yu. M. Lopatin
Volgograd State Medical University
Russian Federation

MD, PhD, Professor Head of the Department of Cardiology and Functional Diagnostics of the Volgograd State Medical University.

Volgograd.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


S. V. Nedogoda
Volgograd State Medical University
Russian Federation

MD, PhD, Professor, Vice-Rector for Clinical Work and Regional Health Development, Head of the Department of Internal Medicine of the Volgograd State Medical University.

Volgograd.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


V. V. Salukhov
S.M. Kirov Military Medical Academy
Russian Federation

MD, PhD, Professor Head of the 1st Department (Therapy for Advanced Training of Doctors) S.M. Kirov Military Medical Academy.

Saint-Petersburg.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


M. Yu. Sitnikova
V.A. Almazov National research medical center of Russian Ministry of Healthcare; Pavlov First State Medical University
Russian Federation

MD, PhD, Professor of the Department of Therapy of National research medical center named after V. A. Almazov.

Saint-Petersburg.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


S. N. Tereshchenko
National Medical Research Center for Cardiology
Russian Federation

MD, PhD, Professor, head of the Department of myocardial diseases and heart failure National Medical Research Center for Cardiology of the Ministry of health of the Russian Federation.

Moscow.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


S. N. Tolstov
V.I. Razumovsky Saratov State Medical University Russian Ministry of Healthcare
Russian Federation

Professor of the Department of Therapy with courses of cardiology, functional diagnostics and geriatrics, Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of Russia.

Saratov.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


Yu. Sh. Khalimov
S.M. Kirov Military Medical Academy
Russian Federation

MD, PhD, Professor, Chief endocrinologist of the Health Committee of the Government of St. Petersburg, Head of the Department of Military Field Therapy, S.M. Kirov Military Medical Academy.

Saint-Petersburg.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


N. R. Khasanov
Kazan State Medical University
Russian Federation

MD, PhD, Professor, Head of the Department of Propedeutics of Internal Diseases named after Professor S.S. Zimnitsky Kazan State Medical University.

Kazan.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


A. I. Chesnikova
Rostov State Medical University
Russian Federation

MD, PhD, Professor, Professor in the Department of Internal Medicine No.1, Rostov State Medical University.

Rostov.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


V. Giga
University of Belgrade
Czechoslovakia

MD, PhD, Associate Professor of Internal Medicine, School of Medicine, University of Belgrade.

Belgrade.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


M. Paсker
Baylor University
United States

MD, PhD, Distinguished Scholar in Cardiovascular Science, Baylor University.

Dallas.
Competing Interests: The Expert Council was supported by Boehringer Ingelheim.


References

1. Koudstaal S, Pujades-Rodriguez M, Denaxas S, et al. Prognostic burden of heart failure 4. recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017;19(9):1119-1127. doi:10.1002/ejhf.709.5.

2. Jones NR, Roalfe AK, Adoki I, et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fai. 2019;21(11):1306-1325. doi:10.1002/ejhf.1594.6.

3. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39. 7. doi:10.1016/S0140-6736(18)32590-X.

4. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528-2536. doi:10.1161/CIRCULATIONAHA.119.040130.

5. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508-511. doi:10.2337/dci19-0074.

6. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.

7. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190.


Review

For citations:

Arutyunov G.P., Arutyunov A.G., Tarlovskaya E.I., Ametov A.S., Vinogradova N.G., Garganeeva A.A., Glezer M.G., Zhirov I.V., Ilyin M.V., Koziolova N.A., Konradi A.O., Lebedeva A.Yu., Lopatin Yu.M., Nedogoda S.V., Salukhov V.V., Sitnikova M.Yu., Tereshchenko S.N., Tolstov S.N., Khalimov Yu.Sh., Khasanov N.R., Chesnikova A.I., Giga V., Paсker M. Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial. Russian Journal of Cardiology. 2020;25(11):4167. (In Russ.) https://doi.org/10.15829/29/1560-4071-2020-4167

Views: 867


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)

119049, Moscow, ul. Shabolovka, 23-254

Russian Federation

 

Processing of personal data
supported by NEICON (Elpub lab)